Portola Pharmaceuticals, Inc.
) recently announced positive results from a phase II
proof-of-concept study evaluating its Factor Xa inhibitor
antidote, PRT4445. The candidate aims to reverse the Factor Xa
inhibitor's anticoagulant activity in patients suffering from
uncontrolled bleeding or undergoing emergency surgery.
The randomized, placebo-controlled, double-blind, cohort
dose-escalation phase II study assessed the pharmacodynamic and
safety profile of PRT4445 in healthy volunteers who received
Bristol-Myers Squibb Company
) Eliquis, a Factor Xa inhibitor. Eliquis is currently used for
reducing the risk of stroke and systemic embolism in patients
with nonvalvular atrial fibrillation.
Results from the study showed that the use of intravenous PRT4445
in 420 mg dose resulted in more than 95% reversal of the
anticoagulant activity of Eliquis in two minutes. Eliquis'
anticoagulant activity decreased by 80% when the 210 mg dosage of
PRT4445 was administered. The candidate was found to be generally
We remind investors that in Nov 2012, Portola entered into an
agreement with Bristol-Myers Squibb and Pfizer to evaluate
PRT4445 in combination with Eliquis.
Portola is conducting a phase II study evaluating PRT4445 with
another Factor Xa inhibitor, Xarelto. The study intends to
evaluate the efficacy and safety of PRT4445 in combination with
Xarelto across multiple dosages. The study aims to determine the
dose of PRT4445 that will be able to reverse the anticoagulant
activity of Xarelto in case of an uncontrolled bleeding or other
emergency situations. The study is expected to be completed by
We believe PRT4445 has significant revenue potential. Portola
retains worldwide development and commercialization rights to
Portola at present carries a Zacks Rank #3 (Neutral). Other
stocks such as
), carrying a Zacks Rank #1 (Strong Buy), currently look more
BRISTOL-MYERS (BMY): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
PORTOLA PHARMA (PTLA): Free Stock Analysis
To read this article on Zacks.com click here.